

Dr Caroline Ford
 SUPPORTED BY CAN TOO
 TARGETING A NEW
 EPIGENETIC THERAPY
 FOR OVARIAN CANCER




Dr Loretta Lau
 SUPPORTED BY CAN TOO
 TELOMERE MAINTENANCE
 IN NEUROBLASTOMA



Dr Luc Furic
 SUPPORTED BY CAN TOO
 TARGETING TREATMENTS
 FOR PROSTATE CANCER




Dr Steve Lane
 SUPPORTED BY CAN TOO
 TREATMENT OF BLOOD
 DISEASES




Dr Ashley Ng
 SUPPORTED BY CAN TOO
 GENETIC INTERACTIONS
 PREDISPOSING TO
 LEUKAEMIA



Dr David Ziegler
 SUPPORTED BY CAN TOO
 ANTI-APOPTOTIC SIGNALING
 PATHWAYS IN MALIGNANT
 GLIOMAS



Dr Jeremy Henson
 SUPPORTED BY CAN TOO
 ALTERNATIVE LENGTHENING
 OF TELOMERES IN LUNG
 CANCER & PATIENT
 OUTCOMES/DIAGNOSIS




Dr Heidi Hilton
 SUPPORTED BY CAN TOO
 EARLY MALIGNANT
 TRANSFORMATION



Dr Liz Caldon
 SUPPORTED BY CAN TOO
 DNA DAMAGE CHECKPOINTS
 IN CANCER



Dr Xue Qin Yu
 SUPPORTED BY CAN TOO
 STAGE OF CARE PREVALENCE
 FOR PROSTATE CANCER



Dr Jennifer Stone
 SUPPORTED BY CAN TOO,
 CHERIE KEETLEY NORTH POD
 UNDERSTANDING
 MAMMOGRAPHIC DENSITY
 AS A PREDICTOR OF BREAST
 CANCER RISK



Dr Xiaomeng Zhang
 SUPPORTED BY CAN TOO
 HIPPO TUMOUR
 SUPPRESSOR PATHWAY
 IN BREAST CANCER



Dr Katie Ashton
 SUPPORTED BY CAN TOO
 A GENETIC INVESTIGATION
 OF MUTYH IN MELANOMA
 DEVELOPMENT